Navigation Links
Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Date:2/27/2012

ease see attached prescribing information.  For additional information about INOMAX, please visit www.inomax.com

About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com.Company Contact:Media Contact:Samina Bari

Claire SojdaIkaria, Inc.

Tiberend Strategic Advisors, Inc.(908) 238-6372  

(212) 827-0020samina.bari@ikaria.com


SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
2. Ikaria® to Present at 2011 BIO Investor Forum
3. Ikaria® To Present at 2011 BIO Business Forum and International Convention
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
6. Auxogyn Completes $20 Million In Series A Funding
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. MiMedx Group Completes $5,000,000 Private Placement
9. PDL BioPharma Completes Regular Quarterly Dividend Payment
10. CeNeRx BioPharma Completes $4.85 Million Financing
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... update on the status of the Company,s Series ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... and 21 shares of Series A Preferred Stock ...
(Date:5/26/2015)... Regenestem Network has announced the grand ... Aires, Argentina. The clinic will be lead by Silvina ... assembled a multidisciplinary team of medical professionals who specialize ... Madero office. , The new Regenestem Network members ... studies in cellular therapies, and establish Regenestem protocols to ...
(Date:5/26/2015)... CITY, California and HILDEN, ... QIAGEN N.V. (NASDAQ: QGEN ; ... launch of its QIAGEN Clinical Insight ® ... testing labs to interpret and report on genomic ... two supported applications for the bioinformatics platform are ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
... NeoStem Shareholders, We would like to take a ... for NeoStem (NYSE Amex: NBS ) – and to ... the company forward in 2012 and beyond. , We have ... LLC ("Amorcyte"). , We believe our therapeutic product development team ...
... LA JOLLA, Calif., Jan. 2, 2012 Renowned biochemist ... and CEO of The Scripps Research Institute January 1, ... for more than two decades. (Photo:  ... opportunity to advance the institute,s mission, creating knowledge in ...
... Dec. 28, 2011  MiMedx Group, Inc. (OTCBB: MDXG), ... protected regenerative biomaterials and bioimplants processed from human ... private placement offering to sell convertible notes and ... the offering, which commenced on October 15, 2011, ...
Cached Biology Technology:NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Michael A. Marletta Takes Office as New President of Scripps Research Institute 2MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... manufacturers in China . The order value ... of + 1 000 MSEK for 2015.   Jörgen ...
(Date:5/6/2015)... May 6, 2015 LifeBEAM, a developer of ... producer, announced today that they will expand their partnership ... first bio-sensing cycling helmet and the first joint project ... new colors in order to give cyclists more style ... addition, LifeBEAM and Lazer announced their plan to release ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... may be onto an ocean of discovery because of his ... The research is likely to lead to making ceramics ... armour many times stronger. These findings were published in ... and focused on the mantis shrimp,s ability to shatter aquarium ...
... within the next five years and in ten years from ... today: what we are going to see at ESMO 2012 ... technologies can improve the tailoring of cancer therapies for the ... President More than 17,000 participants from over 120 different ...
... /PRNewswire-iReach/ -- FirstMark, the diagnostic division of ... Shah has joined its Scientific Advisory Board. ... Director of the Division of Cardiology. He also is ... Cedars-Sinai Medical Center where he leads several studies that ...
Cached Biology News:NTU researchers study little mighty creature for scientific breakthrough 2NTU researchers study little mighty creature for scientific breakthrough 3ESMO 2012 Congress: A path for medical oncology innovations 2ESMO 2012 Congress: A path for medical oncology innovations 3ESMO 2012 Congress: A path for medical oncology innovations 4FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board 2FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board 3
Lysozyme C (W-20)...
... Blood bank refrigerators: ,Each upright model ... superior 4C temperature uniformity for refrigerated blood. ... 2000 Surveillance Module for complete blood storage ... are equipped with the HemaPro 101 alarm/monitor. ...
... RNase H- Reverse Transcriptase ... version of SuperScript™ II ... SuperScript™ II it synthesizes ... from single-stranded RNA DNA ...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
Biology Products: